ScreenerHero

SLXN Silexion Therapeutics Corp

NAS · US · Healthcare · Biotechnology · silexion.com
0.2536USD-3.50%Mkt Cap: 3.67M $P/E: —

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of sol…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.67M USD
Enterprise Value642.24K USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.91M USD
Revenue/Share—
Last Price0.2536 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees13
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.41
PEG—
EV/EBITDA-0.05
EV/Revenue—
P/S—
P/B32.85
EPS (TTM)-27.21
EPS (Forward)-0.64
52W Range
0.23800% of range42.60
52W High42.60 USD
52W Low0.2380 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-457.63%
ROA-165.10%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.82M USD
CapEx (TTM)9.00K USD
FCF Margin—
FCF Yield—
Net Debt-819.00K USD
Net Debt/EBITDA0.06
Balance Sheet
Debt/Equity0.78
Current Ratio0.94
Quick Ratio0.56
Book Value/Sh0.0080 USD
Cash/Share0.40 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateMay 29, 2026
Analyst Consensus
Rating—
Target (Mean)5.000 USD
Upside (mean)+1871.6%
Target Range5.000 USD – 5.000 USD
# Analysts1
Ownership
Shares Out.5.76M
Float5.56M
Insiders36.93%
Institutions0.79%
Short Interest
Short Ratio0.0d
Short % Float4.28%
Short % Out.4.15%
Shares Short238.62K
Short (prev mo.)119.29K
Technical
SMA 500.7181 (-64.7%)
SMA 2008.750 (-97.1%)
Beta-0.30
S&P 52W Chg15.78%
Avg Vol (30d)16.78M
Avg Vol (10d)39.66M
Technical Indicators
RSI (14)28.3
MACD-0.2434
MACD Signal-0.3111
MACD Hist.+0.0677
BB Upper0.4385 USD
BB Middle0.3189 USD
BB Lower0.1992 USD
BB Width75.06%
ATR (14)0.0968 USD
Vol Ratio (20d)0.04x